EX-99.1 2 pdex_ex99z1.htm PRESS RELEASE Press Release

 


EXHIBIT 99.1

[pdex_ex99z1001.jpg]


Contact:  Richard L. Van Kirk, Chief Executive Officer

(949) 769-3200


For Immediate Release


PRO-DEX, INC. ANNOUNCES FISCAL 2020 FIRST QUARTER RESULTS


IRVINE, CA, November 7, 2019 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2020 first quarter ended September 30, 2019.


Net sales for the three months ended September 30, 2019, increased $324,000, or 5%, to $7.2 million from $6.9 million for the three months ended September 30, 2018. The increase is driven by increased sales to our largest customer, primarily increased repair revenue.


Gross profit for the three months ended September 30, 2019, remained fairly flat, increasing $53,000, or 2%, to $2.8 million, compared to $2.7 million for the year-ago period. Gross margin decreased by 1 percentage point to 38% during the three months ended September 30, 2019, compared to 39% during the corresponding year-ago period.


Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2019 increased $290,000 from the corresponding year-ago period. We are increasing these expenditures in an effort to release new products and garner new customer relationships.


Net income for the quarter ended September 30, 2019, was $1.1 million, or $0.27 per diluted share, compared to $1.3 million or $0.31 per diluted share, for the quarter ended September 30, 2018.


CEO Comments


Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our first quarter results, which include another record-breaking sales level in excess of $7 million. We continue to reinvest our profits in both research and development and business development to continue to grow our core medical device business. Finally,” concluded Mr. Van Kirk, “we have experienced delays in our planned product launches as we modify our thoracic driver to meet our customer’s specific needs.”


The amount spent on projects under development, along with the current estimated commercial launch date and estimated recurring annual revenue is summarized below (in thousands):


 

 

For the Three Months Ended September 30,

 

 

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Market Launch

 

 

Est. Annual Revenue

 

Total Research & Development costs:

 

$

484

 

 

$

408

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Products in development:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Thoracic Driver

 

$

19

 

 

$

75

 

 

 

03/20

 

 

$

4,000

 

Arthroscopic Shaver

 

 

6

 

 

 

22

 

 

 

06/20

 

 

$

600

 

Arthroscopic Attachment

 

 

 

 

 

6

 

 

 

12/19

 

 

$

150

 

CMF Driver

 

 

17

 

 

 

 

 

 

06/20

 

 

$

350

 

Sustaining & Other

 

 

442

 

 

 

305

 

 

 

 

 

 

 

 

 

Total

 

$

484

 

 

$

408

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer CMF Driver (1)

 

$

99

 

 

$

54

 

 

 

12/19

 

 

$

2,500

 


(1)

Costs incurred related to customer contracts are included in costs of sales and deferred costs and are not included in research and development costs.





 


The completion of our thoracic driver is currently a priority for our engineering team. The costs in the table above represent our costs related to our Pro-Dex branded driver, which is substantially complete. As we previously discussed, in early fiscal 2019 we entered a development contract with a current significant customer to private-label this driver for their unique specifications. We have had technical delays related to performance of this driver with a specific customer attachment. We currently believe we will launch this product in the third quarter of this fiscal year and have delayed the anticipated launch of most other products to focus on the completion of this thoracic driver.


About Pro-Dex, Inc.:


Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Pro-Dex also sells compact pneumatic air motors for a variety of industrial applications. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.


Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.


(tables follow)





 


PRO-DEX, INC.

CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands, except share amounts)


 

 

September 30,
2019

 

 

June 30,
2019

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

6,502

 

 

$

7,742

 

Investments

 

 

3,127

 

 

 

2,649

 

Accounts receivable, net of allowance for doubtful accounts of $12 and $0 at September 30, 2019 and at June 30, 2019, respectively

 

 

3,157

 

 

 

4,100

 

Deferred costs

 

 

493

 

 

 

430

 

Inventory

 

 

6,844

 

 

 

6,239

 

Prepaid expenses and other current assets

 

 

232

 

 

 

623

 

Total current assets

 

 

20,355

 

 

 

21,783

 

Equipment and leasehold improvements, net

 

 

2,653

 

 

 

2,726

 

Right of use asset, net

 

 

3,187

 

 

 

 

Intangibles, net

 

 

129

 

 

 

129

 

Deferred income taxes, net

 

 

301

 

 

 

260

 

Investments

 

 

1,306

 

 

 

582

 

Other assets

 

 

40

 

 

 

40

 

Total assets

 

$

27,971

 

 

$

25,520

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,376

 

 

$

1,996

 

Accrued expenses

 

 

1,306

 

 

 

1,437

 

Deferred revenue

 

 

240

 

 

 

215

 

Note payable and capital lease obligations

 

 

624

 

 

 

622

 

Total current liabilities

 

 

3,546

 

 

 

4,270

 

Deferred rent

 

 

 

 

 

146

 

Lease liability, net of current portion

 

 

3,015

 

 

 

 

Income taxes payable

 

 

191

 

 

 

162

 

Notes and capital leases payable, net of current portion

 

 

3,775

 

 

 

3,934

 

Total non-current liabilities

 

 

6,981

 

 

 

4,242

 

Total liabilities

 

 

10,527

 

 

 

8,512

 

Shareholders’ equity:

 

 

 

 

 

 

 

 

Common shares; no par value; 50,000,000 shares authorized; 3,990,995 and 4,039,491 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively

 

 

15,161

 

 

 

15,815

 

Accumulated other comprehensive loss

 

 

(606

)

 

 

(549

)

Retained earnings

 

 

2,889

 

 

 

1,742

 

Total shareholders’ equity

 

 

17,444

 

 

 

17,008

 

Total liabilities and shareholders’ equity

 

$

27,971

 

 

$

25,520

 






 


PRO-DEX, INC.

CONDENSED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except share and per share amounts)


 

 

Three Months Ended
September 30,

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

Net sales

 

$

7,240

 

 

$

6,916

 

Cost of sales

 

 

4,460

 

 

 

4,189

 

Gross profit

 

 

2,780

 

 

 

2,727

 

 

 

 

 

 

 

 

 

 

Operating (income) expenses:

 

 

 

 

 

 

 

 

Selling expenses

 

 

142

 

 

 

33

 

General and administrative expenses

 

 

663

 

 

 

565

 

Gain on disposal of equipment

 

 

 

 

 

(7

)

Research and development costs

 

 

484

 

 

 

408

 

Total operating expenses

 

 

1,289

 

 

 

999

 

Operating income

 

 

1,491

 

 

 

1,728

 

Other income (expense):

 

 

 

 

 

 

 

 

Interest and miscellaneous income

 

 

35

 

 

 

74

 

Interest expense

 

 

(59

)

 

 

(20

)

Total other income (expense)

 

 

(24

)

 

 

54

 

 

 

 

 

 

 

 

 

 

Income before income taxes

 

 

1,467

 

 

 

1,782

 

Provision for income taxes

 

 

363

 

 

 

433

 

Net income

 

 

1,104

 

 

 

1,349

 

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

Unrealized gain (loss) from marketable equity investments, net of taxes

 

 

(57

)

 

 

298

 

Comprehensive income

 

$

1,047

 

 

$

1,647

 

 

 

 

 

 

 

 

 

 

Basic and diluted income per share:

 

 

 

 

 

 

 

 

Basic net income per share

 

$

0.28

 

 

$

0.31

 

Diluted net income per share

 

$

0.27

 

 

$

0.31

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

4,008,017

 

 

 

4,330,636

 

Diluted

 

 

4,110,414

 

 

 

4,372,893

 

Common shares outstanding

 

 

3,990,995

 

 

 

4,249,548

 





 


PRO-DEX, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


 

 

Three Months Ended
September 30,

 

 

 

2019

 

 

2018

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net income

 

$

1,104

 

 

$

1,349

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

138

 

 

 

88

 

Share-based compensation

 

 

12

 

 

 

10

 

Non-cash lease expense

 

 

13

 

 

 

 

Amortization of loan fees

 

 

2

 

 

 

 

Gain on disposal of equipment

 

 

 

 

 

(7

)

Deferred income tax

 

 

(41

)

 

 

404

 

Bad debt expense (recovery)

 

 

12

 

 

 

(13

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable and other receivables

 

 

931

 

 

 

(655

)

Deferred costs

 

 

(63

)

 

 

(50

)

Inventory

 

 

(605

)

 

 

(172

)

Prepaid expenses and other assets

 

 

391

 

 

 

(152

)

Accounts payable and accrued expenses

 

 

(1,040

)

 

 

(82

)

Deferred revenue

 

 

25

 

 

 

39

 

Income taxes payable

 

 

29

 

 

 

(123

)

Net cash provided by operating activities

 

 

908

 

 

 

636

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of equipment

 

 

(61

)

 

 

(477

)

Purchases of investments

 

 

(1,258

)

 

 

(824

)

Decrease (increase) in intangibles

 

 

(4

)

 

 

1

 

Proceeds from disposal of equipment

 

 

 

 

 

7

 

Net cash used in investing activities

 

 

(1,323

)

 

 

(1,293

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Principal payments on capital lease and notes payable

 

 

(159

)

 

 

(10

)

Borrowings from Minnesota Bank & Trust

 

 

 

 

 

5,000

 

Payment of employee payroll taxes on net issuance of common stock

 

 

 

 

 

(101

)

Proceeds from ESPP Contributions

 

 

15

 

 

 

10

 

Repurchases of common stock

 

 

(681

)

 

 

(1,115

)

Net cash provided by (used in) financing activities

 

 

(825

)

 

 

3,784

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

(1,240

)

 

 

3,127

 

Cash and cash equivalents, beginning of period

 

 

7,742

 

 

 

5,188

 

Cash and cash equivalents, end of period

 

$

6,502

 

 

$

8,315